Douglas Flora: MRD is actually telling us there’s a residual ember
Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare and ACCC President-Elect, shared a post by Haystack MRD™ by Quest Diagnostics, adding:
“I enjoyed taping this discussion on advances in MRD with the esteemed Debra Patt. Lots more conversations on the role of these tests across a variety of tumor types about to happen. Well done Liz Holland, Kiri Burrow, and Jared Snider.
I think 2025 is the year MRD moves into primetime. Hundreds of studies, increasing sensitivity and a universal predictor of prognosis that informs better decisions in our clinics.
More to come in coming months from AI in Precision Oncology on this important topic.”
Quoting Haystack MRD™ by Quest Diagnostics‘ post:
” ‘MRD is actually telling us there’s a residual ember.’ – Douglas Flora
When minimal residual disease (MRD) is detected, the opportunity to act early and extinguish that ember before it reignites is critical.
Join leading oncologists Dr Doug Flora and Dr Debra Patt as they discuss how cutting-edge MRD testing is shaping the future of cancer diagnostics and treatment decisions.
Learn how these tools are helping to:
- Minimize treatment burdens’
- Guide personalized care
- Build patient confidence
Start your deep dive here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023